Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3BCHECHRM1CHRM2CHRM3CHRM4CHRNA3CHRNA4CHRNB2CHRNB4ESR1ESR2GABRA1GABRB1GABRG2GBA1GHSRHRH1HTR1DHTR2AMAOBOPRD1OPRK1OPRM1SLC6A2SLC6A3TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8UGCGrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Cadaverine Tartrate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | CA4 | P22748 | 2/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.30 |
| ▸ | PGD | P52209 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cadaverine Tartrate SCHEMBL1736550 | 0.94 | TSHR (0.62) | TSHRLMNACYP3A4TDP1BLM | |
| Cadaverine Tartrate SCHEMBL5110910 | 0.94 | TSHR (0.62) | TSHRLMNACYP3A4TDP1BLM | |
| Cadaverine Tartrate SCHEMBL21436375 | 0.94 | TSHR (0.62) | TSHRLMNACYP3A4TDP1BLM | |
| Cadaverine Tartrate SCHEMBL10920631 | 0.94 | TSHR (0.62) | TSHRLMNACYP3A4TDP1BLM | |
| Cadaverine Tartrate SCHEMBL10954371 | 0.94 | TSHR (0.62) | TSHRLMNACYP3A4TDP1BLM | |
| Cadaverine Tartrate SCHEMBL3196371 | 0.94 | TSHR (0.62) | TSHRLMNACYP3A4TDP1BLM | |
| Cadaverine Tartrate SCHEMBL2474192 | 0.90 | TSHR (0.67) | TSHRLMNACYP3A4TDP1BLM | |
| Cadaverine Tartrate SCHEMBL21569383 | 0.90 | TSHR (0.67) | TSHRLMNACYP3A4TDP1BLM | |
| Cadaverine Tartrate SCHEMBL6229409 | 0.90 | TSHR (0.67) | TSHRLMNACYP3A4TDP1BLM | |
| Cadaverine Tartrate SCHEMBL21569402 | 0.90 | TSHR (0.67) | TSHRLMNACYP3A4TDP1BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2582660-B1 | NEW CATHEPSIN S PROTEASE INHIBITORS, USEFUL IN THE TREATMENT OF E.G. AUTOIMMUNE DISORDERS, ALLERGY AND CHRONIC PAIN CONDITIONS | MEDIVIR UK LTD (GB) | 2015-07-22 | — | — | EP | disclosed |
| US-20150025250-A1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR UK LTD | 2015-01-22 | — | — | US | disclosed |
| US-8859605-B2 | Cysteine protease inhibitors | MEDIVIR UK LTD (GB) | 2014-10-14 | — | — | US | disclosed |
| US-8859505-B2 | Cysteine protease inhibitors | MEDIVIR UK LTD (GB) | 2014-10-14 | — | — | US | disclosed |
| US-8853281-B2 | Cysteine protease inhibitors | MEDIVIR UK LTD (GB) | 2014-10-07 | — | — | US | disclosed |
| US-8815809-B2 | Cysteine protease inhibitors | MEDIVIR UK LTD (GB) | 2014-08-26 | — | — | US | disclosed |
| EP-2509956-B1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR UK LTD (GB) | 2014-07-23 | — | — | EP | disclosed |
| EP-2752404-A1 | Cysteine protease inhibitors | Medivir UK Ltd (GB) | 2014-07-09 | — | — | EP | disclosed |
| US-20130172232-A1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR UK LTD (GB) | 2013-07-04 | — | — | US | disclosed |
| EP-2582660-A1 | NEW CATHEPSIN S PROTEASE INHIBITORS, USEFUL IN THE TREATMENT OF E.G. AUTOIMMUNE DISORDERS, ALLERGY AND CHRONIC PAIN CONDITIONS | Medivir UK Ltd (GB) | 2013-04-24 | — | — | EP | disclosed |
| US-20120309673-A1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR UK LTD (GB) | 2012-12-06 | — | — | US | disclosed |
| US-20120283305-A1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR UK LTD (GB) | 2012-11-08 | — | — | US | disclosed |
| EP-2509956-A1 | CYSTEINE PROTEASE INHIBITORS | Medivir UK Ltd (GB) | 2012-10-17 | — | — | EP | disclosed |
| EP-2509957-A1 | CYSTEINE PROTEASE INHIBITORS | Medivir UK Ltd (GB) | 2012-10-17 | — | — | EP | disclosed |
| WO-2011158197-A1 | NEW CATHEPSIN S PROTEASE INHIBITORS, USEFUL IN THE TREATMENT OF E.G. AUTOIMMUNE DISORDERS, ALLERGY AND CHRONIC PAIN CONDITIONS | MEDIVIR UK LIMITED (GB) | 2011-12-22 | — | — | WO | disclosed |
| US-20110312964-A1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR UK LTD (GB) | 2011-12-22 | — | — | US | disclosed |
| EP-2358692-A1 | CYSTEINE PROTEASE INHIBITORS | Medivir UK Ltd (GB) | 2011-08-24 | — | — | EP | disclosed |
| WO-2011070539-A1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR UK LIMITED (GB) | 2011-06-16 | — | — | WO | disclosed |
| WO-2011070541-A1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR UK LIMITED (GB) | 2011-06-16 | — | — | WO | disclosed |
| WO-2010070615-A1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR UK LTD (GB) | 2010-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312964-A1 | CYSTEINE PROTEASE INHIBITORS | CTSS, CTSB, CTSV | TSHR 2037/4885LMNA 2305/4885CYP3A4 1277/4885 |
| US-20150025250-A1 | CYSTEINE PROTEASE INHIBITORS | CTSB, CTSS, CTRB1 | TSHR 1228/4885LMNA 2135/4885CYP3A4 1012/4885 |
| US-20120309673-A1 | CYSTEINE PROTEASE INHIBITORS | CTSB, CTSS, CTRB1 | TSHR 1353/4885LMNA 2421/4885CYP3A4 1194/4885 |
| US-20120283305-A1 | CYSTEINE PROTEASE INHIBITORS | CTSS, CTSB, CTRB1 | TSHR 1384/4885LMNA 1709/4885CYP3A4 1394/4885 |
| US-20130172232-A1 | CYSTEINE PROTEASE INHIBITORS | CTSB, CTSS, CTRB1 | TSHR 1228/4885LMNA 2135/4885CYP3A4 1012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.